Mabwell Announces Acceptance of Supplemental Biologics License Application by NMPA for MAIWEIJIAN (Denosumab)

Why It Matters

The acceptance moves the biosimilar toward a large oncology market, giving Mabwell a first‑mover edge in China and a platform for global expansion, while offering clinicians a safer alternative to bisphosphonates.

Key Takeaways

• NMPA accepts supplemental BLA for MAIWEIJIAN denosumab biosimilar.
• First 120 mg denosumab biosimilar launched in China, early‑mover advantage.
• Approved in Pakistan; agreements signed in 33 countries, 8 pending registrations.
• Shows comparable PK/PD, efficacy, safety to reference product in trials.
• Targets RANKL, superior to bisphosphonates, reduces renal toxicity.

Pulse Analysis

Denosumab, a monoclonal antibody that blocks RANKL, has become a cornerstone in managing bone complications from cancer. In China, the biosimilar market is still nascent, and regulatory pathways favor domestic innovators that can demonstrate equivalence to reference biologics. Mabwell’s MAIWEIJIAN, the first 120 mg denosumab biosimilar cleared by the NMPA, taps into a growing demand for cost‑effective oncology supportive care, especially as the country expands its cancer treatment infrastructure and reimbursement schemes.

The clinical dossier for MAIWEIJIAN includes Phase I and Phase III data published in International Immunopharmacology and JAMA Oncology, showing pharmacokinetic, pharmacodynamic, efficacy, and safety profiles that mirror the reference product. Compared with traditional bisphosphonates, denosumab offers targeted RANKL inhibition, superior control of skeletal‑related events, and a favorable renal safety profile—critical for patients with compromised kidney function. These attributes have been reinforced by head‑to‑head trials in patients with bone metastases from solid tumors, positioning the biosimilar as a compelling therapeutic alternative.

From a business perspective, the supplemental BLA acceptance unlocks a sizable market segment estimated at billions of dollars globally. Mabwell’s existing agreements across 33 countries and pending registrations in eight more provide a rapid go‑to‑market pathway, reducing reliance on a single geography. The move also strengthens the company’s pipeline credibility, potentially attracting partnership opportunities and capital inflows as investors seek exposure to high‑growth biopharma assets focused on oncology and aging‑related diseases.